0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Malignant Mesothelioma - Epidemiology Forecast to 2028
Published Date: February 2019
|
Report Code: DELV-Epid-211
Home | Market Reports |Health |Health Conditions |Cancer
Malignant Mesothelioma Epidemiology Forecast to 2028

Malignant Mesothelioma - Epidemiology Forecast to 2028

Code: DELV-Epid-211
Report
February 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Malignant Mesothelioma - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Malignant Mesothelioma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Malignant Mesothelioma Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Malignant Mesothelioma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Malignant Mesothelioma outlook. It also includes the explanation of changing trends of epidemiology outlining the Malignant Mesothelioma scenario.

Malignant Mesothelioma Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Malignant Mesothelioma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Malignant Mesothelioma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Malignant Mesothelioma Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Malignant Mesothelioma

Key assessments
• Patient Segmentation in Malignant Mesothelioma
• Malignant Mesothelioma Risk & Burden
• Factors driving growth in a specific Malignant Mesothelioma patient population

1. Report Introduction
2. Malignant Mesothelioma Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Malignant Mesothelioma in 2016
2.2. Patient Share Distribution of Malignant Mesothelioma in 2028
3. Disease Background and Overview: Malignant Mesothelioma
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Malignant Mesothelioma in 7MM
4.3. Total Prevalent/ Incident Patient Population of Malignant Mesothelioma in 7MM – By Countries
5. Epidemiology of Malignant Mesothelioma by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.1.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.1.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.1.5. Diagnosed Cases of the Malignant Mesothelioma
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.4.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.4.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.4.5. Diagnosed Cases of the Malignant Mesothelioma
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.5.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.5.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.5.5. Diagnosed Cases of the Malignant Mesothelioma
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.6.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.6.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.6.5. Diagnosed Cases of the Malignant Mesothelioma
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.7.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.7.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.7.5. Diagnosed Cases of the Malignant Mesothelioma
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.8.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.8.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.8.5. Diagnosed Cases of the Malignant Mesothelioma
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Malignant Mesothelioma
5.9.3. Sub-Type Specific cases of the Malignant Mesothelioma *
5.9.4. Sex- Specific Cases of the Malignant Mesothelioma *
5.9.5. Diagnosed Cases of the Malignant Mesothelioma
6. Unmet Needs of the Malignant Mesothelioma
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Malignant Mesothelioma in 7MM
Table 2: Total Prevalent/Incident Cases of the Malignant Mesothelioma in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Malignant Mesothelioma in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Malignant Mesothelioma in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Malignant Mesothelioma in United States (2016-2028)*
Table 6: Diagnosed Cases of the Malignant Mesothelioma in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Malignant Mesothelioma in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Malignant Mesothelioma in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Malignant Mesothelioma in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Malignant Mesothelioma in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Malignant Mesothelioma in France (2016-2028)
Table 12: Sub-Type Specific cases of the Malignant Mesothelioma in France (2016-2028) *
Table 13: Sex- Specific Cases of the Malignant Mesothelioma in France (2016-2028) *
Table 14: Diagnosed Cases of the Malignant Mesothelioma in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Malignant Mesothelioma in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Malignant Mesothelioma in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Malignant Mesothelioma in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Malignant Mesothelioma in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Malignant Mesothelioma in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Malignant Mesothelioma in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Malignant Mesothelioma in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Malignant Mesothelioma in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Malignant Mesothelioma in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Malignant Mesothelioma in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Malignant Mesothelioma in UK (2016-2028) *
Table 26: Diagnosed Cases of the Malignant Mesothelioma in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Malignant Mesothelioma in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Malignant Mesothelioma in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Malignant Mesothelioma in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Malignant Mesothelioma in Japan (2016-2028)

List of Figure:

Figure 1: Total Prevalent/Incident Cases of the Malignant Mesothelioma in 7MM
Figure 2: Total Prevalent/Incident Cases of the Malignant Mesothelioma in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Malignant Mesothelioma in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Malignant Mesothelioma in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Malignant Mesothelioma in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Malignant Mesothelioma in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Malignant Mesothelioma in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Malignant Mesothelioma in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Malignant Mesothelioma in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Malignant Mesothelioma in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Malignant Mesothelioma in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Malignant Mesothelioma in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Malignant Mesothelioma in France (2016-2028) *
Figure 14: Diagnosed Cases of the Malignant Mesothelioma in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Malignant Mesothelioma in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Malignant Mesothelioma in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Malignant Mesothelioma in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Malignant Mesothelioma in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Malignant Mesothelioma in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Malignant Mesothelioma in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Malignant Mesothelioma in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Malignant Mesothelioma in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Malignant Mesothelioma in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Malignant Mesothelioma in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Malignant Mesothelioma in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Malignant Mesothelioma in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Malignant Mesothelioma in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Malignant Mesothelioma in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Malignant Mesothelioma in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Malignant Mesothelioma in Japan (2016-2028

SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Seventh Sense AI

RELATED REPORTS

Global Sarcoma Biopsy Device Sales Market Report 2021
Global Sarcoma Biopsy Device Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-25I5504
Thu Jun 24 00:00:00 UTC 2021

Add to Cart

Global Cervical Cancer Vaccine Sales Market Report 2021
Global Cervical Cancer Vaccine Sales Market Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-32Z5461
Thu Jun 24 00:00:00 UTC 2021

Add to Cart

Global Oncology Treatment Drug Market Size Status and Forecast 2021 2027
Global Oncology Treatment Drug Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-12C5642
Tue Jun 22 00:00:00 UTC 2021

Add to Cart

Global Cannabinoid based Products for Cancer Market Size Status and Forecast 2021 2027
Global Cannabinoid-based Products for Cancer Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-26P5460
Tue Jun 22 00:00:00 UTC 2021

Add to Cart